WO2008059728A1 - Capsule-type device for dispensing medicament - Google Patents

Capsule-type device for dispensing medicament Download PDF

Info

Publication number
WO2008059728A1
WO2008059728A1 PCT/JP2007/071513 JP2007071513W WO2008059728A1 WO 2008059728 A1 WO2008059728 A1 WO 2008059728A1 JP 2007071513 W JP2007071513 W JP 2007071513W WO 2008059728 A1 WO2008059728 A1 WO 2008059728A1
Authority
WO
WIPO (PCT)
Prior art keywords
capsule
dosing
opening
space
drug
Prior art date
Application number
PCT/JP2007/071513
Other languages
French (fr)
Japanese (ja)
Inventor
Mitsuru Kobayashi
Original Assignee
Panasonic Electric Works Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2006312029A external-priority patent/JP2008125641A/en
Priority claimed from JP2006312030A external-priority patent/JP2008125642A/en
Application filed by Panasonic Electric Works Co., Ltd. filed Critical Panasonic Electric Works Co., Ltd.
Publication of WO2008059728A1 publication Critical patent/WO2008059728A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/07—Endoradiosondes
    • A61B5/073—Intestinal transmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time

Definitions

  • the present invention relates generally to a dosing device, and more particularly to a capsule-type dosing device.
  • Such a capsule-type dispensing device has already been proposed.
  • Japanese Patent Application Publication No. 2005-185567 discloses a medical capsule device.
  • the main unit is an observation means for observing the inside of the digestive tract, a communication means for transmitting / receiving a signal to / from an external device, and a drug release for receiving a signal from the communication means to control a drug release operation.
  • Control means are provided.
  • the medicine unit is provided with an injection nozzle for containing the medicine and injecting the medicine, and an opening / closing means for opening or closing the injection nozzle.
  • the opening and closing means is made of a soluble membrane that dissolves in the extinguishing tube.
  • the opening / closing means that is, the soluble film
  • the ejection nozzle is eventually opened. Then, while watching the image displayed on the monitor device, the operator waits until the device reaches a desired part. When the device reaches a desired site, the operator transmits a control signal to the main unit. The device receives the control signal and injects the drug into the digestive tract through the injection nozzle.
  • An object of the present invention is to reliably administer a drug to a desired site in the digestive tract.
  • the capsule-type dosing device of the present invention includes a capsule to be administered into the digestive tract, a storage space having a medication opening and formed on one end side of the capsule, and a medicine stored in the storage space Agents and plugs that plug the dosing opening.
  • the apparatus further comprises a movable wall and a drive system.
  • the movable wall is movably placed in the storage space and is formed so as to partition the storage space into a first space and a second space.
  • the first space includes a medication opening and is configured to store a medication.
  • the drive system is configured to remove the stopper from the dosing opening and move the movable wall toward the dosing opening to dispense the drug into the gastrointestinal tract in accordance with a dosing command.
  • the drug can be reliably administered to a desired site in the digestive tract.
  • the movable wall is made of a permanent magnet.
  • the drive system includes a pair of spiral coils and an excitation circuit.
  • Each of the spiral coils is formed on both walls of the wall surrounding the storage space facing both sides of the movable wall.
  • the excitation circuit is configured to supply power to each of the spiral coil so as to move the movable wall toward the medication opening in accordance with the medication command.
  • the movable wall can be moved toward the dosing opening by each magnetic field of the coil, so that the drug can be administered into the digestive tract after the stopper is removed from the dosing opening.
  • the stopper plugs the dosing opening by a loose fit.
  • the drive system is configured to dispense the drug into the extinguishing tube by moving the movable wall toward the dosing opening and removing the stopper from the dosing opening.
  • the movable wall moves toward the medication opening and the pressure in the first space is increased, so that the stopper is pushed out of the medication opening.
  • the medication opening is opened, and the drug in the first space is administered into the digestive tract through the medication opening. Accordingly, since the stopper is removed before the device reaches the desired site, it can be prevented, so that it is possible to prevent the medicine from leaking out before reaching the desired site.
  • the stopper is removed from the dosing opening according to the dosing instruction, the drug can be smoothly administered into the digestive tract.
  • the plug is made from a material that is melted at a melting point that is higher than the temperature in the digestive tract.
  • the drive system is configured to release the plug opening force by melting the plug with the Joule heat of the spiral opening coil on the drug opening side, and subsequently dispense the drug into the gastrointestinal tract.
  • the stopper since the stopper is melted by Joule heat of the coil on the side of the medication opening, the fitting of the stopper to the medication opening can be loosened. Therefore, it is easy to remove the stopper I can do it.
  • the stopper can be strongly fitted into the medication opening, it is possible to prevent the medicine from leaking from the gap between the stopper and the medication opening.
  • the apparatus further comprises a meltable wall made of a meltable film that is melted at a melting point higher than the temperature in the digestive tract, and that partitions the second space into a plurality of working chemical chambers.
  • the drive system includes various types of agonists, a heater, and a heater drive circuit. Each type of agonist is stored in the agonist chamber and mixed to expand the volume.
  • the heater is formed on the wall surrounding the storage space.
  • the heater drive circuit is configured to supply power to the heater in accordance with a medication instruction. In the present invention, when the heater driving circuit supplies power to the heater, the heater heats the meltable wall in the storage space, so that the meltable wall is melted.
  • the stopper closes the medication opening by a loose fit.
  • the drive system is configured to dispense the plug into the gastrointestinal tract while moving the movable wall toward the dosing opening and removing the stopper from the dosing lock.
  • the movable wall moves to the side of the medication opening due to the expansion of various types of agonist, the pressure in the first space is increased and the stopper is pushed out of the medication opening.
  • the medication opening is opened, and the drug in the first space is administered into the digestive tract through the medication opening. Accordingly, since the stopper is removed before the device reaches the desired site, it is possible to prevent the device from leaking before reaching the desired site.
  • the opening force of the plug is also released in accordance with the medication command, the drug can be reliably administered into the digestive tract.
  • the plug may be made from a material that is melted at the melting point! /.
  • the plug when the surface of the stopper is melted by the heater, the gap between the stopper and the medication opening is increased, so that the stopper can be easily removed. As a result, the drug can be reliably administered to a desired site.
  • the device includes a plurality of drugs as the drug.
  • the meltable wall is formed so as to extend through the movable wall to the first space so that the first space is also divided into a plurality of drug chambers.
  • multiple drugs can be stored in multiple drug rooms. Stored.
  • various drugs that are preferably separated in advance can be stored in a plurality of drug chambers, and various drugs can be simultaneously applied to desired sites. Therefore, various drugs can be administered to the desired site.
  • the stopper and the meltable wall are made from beef tallow and are integrated with each other.
  • the stopper when the meltable wall is melted, the stopper is also melted, so that the medication opening can be reliably opened and the drug can be smoothly administered into the digestive tract.
  • the stopper and the meltable wall are made of beef tallow with a melting point of 40-45 ° C, it is difficult to melt at temperatures in the digestive tract.
  • the stopper and meltable wall are melted and absorbed into the subject's body, they are not harmful to health.
  • FIG. 1 is a schematic longitudinal sectional view of a capsule dosing device according to a first embodiment of the present invention.
  • FIG. 2 is a schematic longitudinal sectional view of the dosing device after dosing.
  • FIG. 3 is a schematic view of a coil of the dosing device.
  • FIG. 4 is a flow diagram of manufacturing technology for each coil of the dosing device.
  • FIGS. 5A to 5C are perspective views of the MID in each process of the manufacturing technique.
  • FIG. 6A and FIG. 6B are perspective views of MID in each process of the manufacturing technique.
  • FIG. 7 is a schematic longitudinal sectional view of a capsule dosing device according to a second embodiment of the present invention.
  • FIG. 8 is a schematic longitudinal sectional view of the dosing device after dosing.
  • FIG. 9 is a schematic view of a heater of the dosing device.
  • FIG. 1 shows a capsule-type dispensing device A according to a first embodiment of the present invention.
  • the capsule-type dosing device A includes a capsule 1 made of a heat resistant material such as ceramic or polyetheretherketone (PEEK).
  • the capsule 1 is formed, for example, in an oval shape or a cylinder shape. In the example of FIG. 1, the capsule 1 has a cylindrical shape.
  • the inside of the capsule 1 is left by a fixed wall 2 arranged in the middle part in the axial direction (vertical direction) Divided into right storage spaces 3 and 4.
  • the left accommodation space 3 is provided with a movable wall 5.
  • the movable wall 5 is composed of a planar permanent magnet that is slightly smaller than the cross section of the accommodation space 3, and is placed in the accommodation space 3 so as to move freely in the axial direction.
  • the first space 3a for accommodating the medicine 8 to be administered is formed of a space sandwiched between the left end face of the accommodation space 3 and the movable wall 5.
  • a medication opening 6 for example, a through hole
  • the dosing opening 6 is closed from the outside with a stopper 7 by loose fitting (gap fitting).
  • the plug 7 is made of a material (eg, beef tallow) that is melted at a melting point (eg, 40-45 ° C) higher than the temperature in the digestive tract.
  • the capsule 1 is further formed with a vent hole (not shown) for opening the space between the movable wall 5 and the fixed wall 2 to the outside!
  • a pair of spiral coil coils 9 and 10 are formed on the surface 2a on the side of the accommodation space 4 in the fixed wall 2 and the inner surface la of the left end of the capsule 1 by a MID (molded interconnect device) manufacturing technique, respectively.
  • the manufacturing technique will be described later.
  • FIG. 3 is a schematic diagram of the coil 9 formed on the surface 2 a of the fixed wall 2.
  • the outer end of the spiral coil 9 is a terminal 9a connected to a battery 34 described later.
  • the inner end of the spiral coil 9 is electrically connected to the conductive pattern 11 formed on the back surface through the through hole 2b.
  • the conductive pattern 11 is electrically connected to one end of a conductive line 12 which is a metal plating layer formed on the top of the accommodation space 3 in the axial direction.
  • the other end of the conductive line 12 is electrically connected to a conductive pattern 13 formed on the outer surface of the left end of the capsule 1 via a through hole lb formed on the left end.
  • the conductive pattern 13 is formed on the outer surface of the left end of the capsule 1 from the outer edge to the center side.
  • the end of the conductive pattern 13 on the center side is electrically connected to the inner end of the spiral coil 10 formed on the inner surface la of the left end through a through hole lc formed on the left end. Yes.
  • the outer end of the spiral coil 10 is connected to a conductive line 14 that is a metal plating layer formed on the bottom of the accommodation space 3 in the axial direction.
  • a terminal 15 that is electrically connected to the conductive line 14 is formed on the surface 2 a of the fixed wall 2. That is, the spiral coils 9 and 10 are connected in series between the terminals 15 and 9a.
  • the storage space 4 stores a control circuit 30 for performing a medication operation according to a medication command (trigger input).
  • the control circuit 30 includes an excitation circuit 31, a communication circuit 32, and a camera 35.
  • the excitation circuit 31 has a switch element (not shown) connected between the terminals 9a and 15 via the battery 34, and the switch element so as to turn on / off the power supply to the spiral coils 9 and 10. Configured to control on / off of the.
  • the communication circuit 32 is configured to transmit and receive radio signals via an antenna 33 to or from a remote control system (not shown) arranged outside the subject's body.
  • the camera 35 is configured to take an image outside the capsule 1, that is, an image in the subject's digestive tract.
  • the communication circuit 32 transmits a radio signal including image data taken through the camera 35 to the remote control system at specified time intervals.
  • the communication circuit 32 gives the medication command to the excitation circuit 31.
  • the excitation circuit 31 turns on the switch element and applies a DC (direct current) voltage of the battery 34 to the spiral coils 9 and 10. As a result, each of the spiral coils 9 and 10 generates a magnetic field.
  • the direction of the winding of the spiral coil 9 and the excitation current is set so that the spiral coil 9 generates a magnetic field for repelling the movable wall 5.
  • the direction of winding and excitation current of the spiral 'coil 10 is set so that the spiral' coil 10 generates a magnetic field for attracting the movable wall 5. Accordingly, the movable wall 5 in the storage space 3 is moved from the fixed wall 2 side to the medication opening 6 side by the magnetic field of the spiral coils 9 and 10.
  • the capsule-type dosing device A has the above-described configuration! Next, a dosing method via the capsule-type dosing device A (also referred to as capsule 1) will be described.
  • the movable wall 5 in the accommodation space 3 is arranged on the fixed wall 2 side, and then the first space 3a is filled with a medicine from the medication opening 6. Thereafter, the stopper 7 is fitted into the dosing opening 6 and the opening is closed (see FIG. 1).
  • the capsule 1 moves in the digestive tract of the subject by its peristaltic movement. In the meantime, the capsule 1 transmits images taken through the camera 35 to the remote control system at specified time intervals.
  • the remote control system starts from capsule 1 Are displayed on the monitor of the remote control system. Therefore, the person in charge of medicine (operator) can grasp the current position of the capsule 1.
  • the operator operates the remote control system to send a radio signal including a medication command. Transmit to capsule 1 from the remote control system.
  • the communication circuit 32 When the communication circuit 32 receives the medication command for the capsule 1! /, The medication command is given to the excitation circuit 31.
  • the excitation circuit 31 turns on the switch element and applies the DC voltage of the notch 34 to the spiral coils 9 and 10. Therefore, the spiral 'coil 9 generates a magnetic field for repelling the movable wall 5, while the spiral' coil 10 generates a magnetic field for attracting the movable wall 5.
  • each of the spiral coils 9 and 10 generates a magnetic force for moving the movable wall 5 toward the dosing opening 6 side.
  • the capsule-type medication device A feeds the spiral coils 9 and 10 and moves the movable wall 5 as a result. 7 is pushed out of the dosing opening 6 and the drug 8 is administered into the gastrointestinal tract.
  • the timing of dosing is strictly controlled by reducing variation in dosing timing, the drug can be reliably administered to a desired site.
  • the movable wall 5 is driven by the magnetic field of the spiral coils 9 and 10, the movable wall 5 can be driven with a substantially constant force, and the drug 8 can be released from the dosing opening 6 at a substantially constant flow rate. it can.
  • FIGS. 4, 5A-5C, and 6A and 6B the MID manufacturing technique used to form the coils 9 and 10 will be described.
  • Figure 4 is a schematic flow diagram of MID manufacturing technology. MID is
  • PVD physical vapor deposition
  • a laser processing step of separating the circuit portion and the non-circuit portion with a high energy beam for example, a laser beam
  • FIGS. 5A-5C and 6A and 6B show the surface treatment states of MID (C) in each step of FIG.
  • FIG. 5A corresponds to the molding step (S1), and a desired three-dimensional MID 21 is molded through injection molding of an insulating synthetic resin.
  • the molding material of MID21 is, for example, aromatic polyamide or liquid crystalline polyester in the case of a thermoplastic resin, or epoxy resin or saturated polyester in the case of a thermosetting resin. In the case of ceramic, nitride anolemina is used.
  • the molding method of MID21 may be extrusion molding or transfer molding!
  • FIG. 5B corresponds to the metallization process (S2), and the conductive thin film 22 is formed on the surface of the MID 21 by a PVD method such as sputtering, vacuum deposition or ion plating of a copper target, for example.
  • a PVD method such as sputtering, vacuum deposition or ion plating of a copper target, for example.
  • the material of the conductive thin film 22 may be a single metal such as nickel, gold, aluminum, titanium, molybdenum, chromium, tantasten, tin or lead, or an alloy such as brass or NiCr.
  • FIG. 5C corresponds to the laser processing step (S3).
  • a high energy beam for example, a laser beam (electromagnetic beam) is irradiated on the boundary portion of the circuit portion 23a and the non-circuit portion 23b in the 1S conductive thin film 22, and the conductive thin film at the boundary portion is evaporated and removed.
  • the circuit portion 23a and the non-circuit portion 23b are separated by the removal portion 23c, and a desired circuit pattern is formed.
  • FIG. 6A corresponds to the fitting process step (S4).
  • Each of the circuit parts 23a is supplied with current.
  • the plated layer 24 is formed by covering with a thick film of electrolytic copper plating. Since each non-circuit portion 23b is not supplied with current, the thickness of each non-circuit portion 23b does not change.
  • FIG. 6B corresponds to the etching process (S5).
  • the entire circuit pattern of MID21 is etched, and the non-circuit portion 23b is removed. As a result, the MID on which the circuit pattern is formed is obtained.
  • Spiral coils 9 and 10 can be formed by such manufacturing techniques.
  • FIG. 7 shows a capsule dosing device B according to a second embodiment of the present invention.
  • the capsule-type dosing device B includes a capsule 1 made of a heat resistant material such as ceramic or PEEK.
  • the capsule 1 is formed, for example, in an oval shape or a cylinder shape. In the example of FIG. 7, the capsule 1 has a cylinder shape.
  • the inside of the capsule 1 is partitioned into left and right accommodation spaces 3 and 4 by a fixed wall 2 disposed in an intermediate portion in the axial direction (vertical direction).
  • the left accommodation space 3 is provided with a movable wall 5.
  • the movable wall 5 is placed in the accommodation space 3 so as to move freely in the axial direction, and the accommodation space 3 can be partitioned into a first (left side) space 3a and a second (right side) space 3b.
  • the first space 3a stores a plurality of medicines.
  • the second space 3b stores various agonists whose volume is expanded by being mixed.
  • a medication opening 6 which is a slit for opening the first space 3a to the outside is formed.
  • the movable wall 5 is formed with a through hole 5a which is disposed at a position corresponding to the medication opening 6 and penetrates the movable wall 5 in the thickness direction of the movable wall 5! /.
  • the storage space 3 is provided with a meltable wall 7A therein.
  • the meltable wall 7A is made of a meltable film (eg, beef tallow) that is melted at a melting point (eg, 40-45 ° C) higher than the temperature in the digestive tract!
  • This meltable wall 7A is inserted into the dosing opening 6 and the through hole 5a, partitions the first space 3a into the upper drug chamber 3a_l and the lower drug chamber 3a_2, and operates the second space 3b as the upper drug chamber 3b_l and the lower drug chamber. Partition into chamber 3b_2.
  • a plug 7 is formed at the tip of the meltable wall 7A so as to protrude from the dosing opening 6 and close the dosing opening 6.
  • the plug 7 is formed to have a thickness larger than the remaining part of the meltable wall 7A.
  • the two types of drugs 8a and 8b are separated. And can be stored in the chambers 3a_l and 3a_2, respectively.
  • the agonist chambers 3b_l and 3b_2 are provided, the two types of agonists 19a and 19b whose volumes expand when mixed can be separated and stored in the agonist chambers 3b_l and 3b_2, respectively.
  • the agonists 19a and 19b are preferably harmless substances because they are excreted into the body of the subject.
  • agonist 19a is preferably an acid such as vinegar or lemon juice
  • agonist 19b is preferably sodium bicarbonate or lemonade sweets.
  • the drug chambers 3a-l and 3a-2 and the working drug chambers 3b-l and 3b-2 are formed with through holes (not shown), and the drugs 8a and 8b and the working chemicals are respectively formed through the through holes.
  • 19a and 19b are filled. After they are filled, each through-hole is sealed, particularly but not limited to, liquids can enter and exit.
  • drugs 8a and 8b and agonists 19a and 19b are sealed in drug chambers 3a_l and 3a_2 and agonist chambers 3b_l and 3b_2, respectively (see FIG. 7).
  • FIG. 9 shows a schematic shape of the coil heater 17 formed on the surface 2 a of the fixed wall 2.
  • One end of the coiled heater 17 is a terminal 17a connected to a battery 34, which will be described later, and the other end is a terminal 17b, which is a conductive metal layer formed on the top of the accommodation space 3 in the axial direction. Connected to one end of line 12.
  • a conductive line 14 which is a metal plating layer formed in the axial direction is also formed at the bottom of the accommodation space 3, and a terminal 15 electrically connected to one end of the conductive line 14 is connected to the fixed wall 2. Formed on the surface 2a. Since the other ends of the conductive lines 12 and 14 are electrically connected to both ends of the coil heater 16 formed on the inner surface la of the capsule 1, respectively, the coil heaters 16 and 17 are connected between the terminals 17a and 15. Connected in series.
  • the storage space 4 stores a control circuit 30 for supplying power to the coiled heaters 16 and 17 in accordance with a medication command (trigger input).
  • the control circuit 30 includes a heater drive circuit 36, a communication circuit 32, and a camera 35.
  • the heater driving circuit 36 is a switching circuit having a switching element (not shown) connected between the terminals 17a and 15 via the battery 34, and controls the on / off of the switching element to produce a coiled heater. Power supply to 16 and 17 Configured to control force.
  • the communication circuit 32 is configured to transmit and receive radio signals via an antenna 33 to or from a remote control system (not shown) arranged outside the subject's body.
  • the camera 35 is configured to take an image outside of the capsule 1, that is, an image in the subject's digestive tract.
  • the communication circuit 32 transmits a radio signal including image data taken through the camera 35 to the remote control system at specified time intervals. Further, when receiving a radio signal including a medication command (heating command) from the remote operation system, the communication circuit 32 gives the medication command to the heater drive circuit 36. Upon receiving a medication instruction from the communication circuit 32, the heater drive circuit 36 supplies a predetermined power to the coiled heaters 16 and 17 by switching the DC voltage of the battery 34, thereby The storage space 3 is heated by the coil heaters 16 and 17 to a predetermined temperature higher than the melting point.
  • the capsule dosing device B has the above-described configuration. Next, a description will be given of a dosing method via the capsule-type dosing device B (both capsules 1).
  • the meltable wall 7A is inserted into the injection opening 6 and the through hole 5a, and the first space 3a and the second space 3b are partitioned into the chemical chambers 3a_l and 3a_2 and the working chemical chambers 3b_l and 3b_2.
  • drug chambers 3a_l and 3a_2 and agonist chambers 3b_l and 3b_2 are filled with drugs 8a and 8b and agonists 19a and 19b, respectively.
  • the capsule 1 moves in the subject's digestive tract by its peristaltic movement. In the meantime, the capsule 1 transmits images taken through the camera 35 to the remote control system at specified time intervals.
  • the remote control system displays each image from the capsule 1 on the monitor of the remote control system. Therefore, the person in charge of medicine (operator) can grasp the current position of the capsule 1.
  • the operator operates the remote control system and includes a medication command (heating command).
  • the wireless signal is transmitted to the capsule 1 from the power of the remote control system.
  • the communication circuit 32 receives the medication command in the capsule 1, the medication command is given to the heater drive circuit 36.
  • the heater drive circuit 36 uses a switching element to switch the DC voltage of the battery 34, thereby supplying a predetermined power to the coiled heater 1 Supply to 6 and 17, thereby causing the coil heaters 16 and 17 to heat the storage space 3 to a predetermined temperature.
  • the meltable wall 7A and the plug 7 are not melted! /. This is because the meltable wall 7A and the plug 7 are made of a material having a melting point higher than the temperature in the digestive tract.
  • the meltable wall 7A and the stopper 7 are melted when the coil heaters 16 and 17 are turned on, so that the medicines in the medicine chambers 3a_l and 3a_2 can be mixed, and the first space 3a becomes the dosing opening 6 It is opened to the outside through.
  • the agonists 19a and 19b in the agonist chambers 3b_l and 3b_2 are mixed.
  • the volume of the agonists 19a and 19b expands and the pressure in the second space 3b is increased, so that the movable wall 5 is moved toward the dosing opening 6 side.
  • the drugs 8a and 8b in the first space 3a are released to the outside through the dosing opening 6 while being mixed.
  • the capsule-type medication device B when the operator transmits a medication command through the remote control system, the capsule-type medication device B turns on the coiled heaters 16 and 17 to melt the meltable wall 7A and the plug 7 As a result, the drug is administered into the digestive tract.
  • the drug since the variation in the timing at which the stopper 7 melts can be reduced, the drug can be reliably administered to a desired site by precisely controlling the timing of dosing.
  • the meltable wall 7A made from beef tallow is extended from the second space 3b to the first space 3a, and the meltable wall 7A and the plug 7 are formed as a single piece, so that they can be melted simultaneously. As a result, the medication opening 6 can be reliably opened and the drug can be smoothly administered into the digestive tract.
  • meltable wall 7A partitions the first space 3a into the drug chambers 3a_l and 3a_2, different drugs that are preferably separated in advance can be stored in the drug chambers 3a_l and 3a_2, respectively. Can be applied simultaneously to the site.
  • the capsule dosing device B includes only the coiled heater 17. This embodiment is effective when the meltable wall 7A and the plug 7 can be melted only by the coil heater 17. In this case, since the conductive lines 12 and 14 are not required, the production is easy.
  • the capsule dosing device B includes a timer circuit (not shown) instead of the camera 35.
  • the timer circuit is configured to wait for a desired waiting time and give a medication command to the heater drive circuit 36.
  • the subject has a capsule dosing device.
  • the heater drive circuit 36 performs a switching operation to supply power to the coiled heaters 16 and 17.
  • the medication timing can be adjusted according to the subject, so that the drug can be reliably administered to the desired site.
  • the plug 7 is formed as a separate piece separated from the meltable wall 7A.
  • This individual piece can be made of a material force that does not change with the heating temperature of the coiled heaters 16 and 17, for example.
  • the meltable wall 7A is melted by the heat generated by the coil heaters 16 and 17, and the working chemicals 19a and 19b are mixed to expand the volume.
  • the movable wall 5 is moved to the side of the medication opening 6 and the pressure in the first space 3a is increased, so that the stopper 7 is pushed out, and subsequently the medications 8a and 8b in the medication chambers 3a_l and 3a_2 are dispensed.
  • the gastrointestinal tract Through the gastrointestinal tract.
  • the plug 7 (individual piece) may be made from a material that is melted at the melting point.
  • the surface of the stopper 7 is melted by the heat generated by the coiled heater 16, and the gap between the stopper 7 and the dosing opening 6 is increased, so that the stopper 7 can be easily removed, and the medicine is reliably delivered to the desired site. Can be administered.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

A capsule-type device for dispensing a medicament, having a capsule, a receiving space having a medicament dispensing opening, a medicament received inside the receiving space, a plug for closing the medicament dispensing opening, a movable wall, and a drive system. The movable wall is movably placed in the receiving space and can partition the space into a first space and a second space. The first space has the medicament dispensing opening and receives the medicament. According to a medicament dispense command, the drive system removes the plug from the medicament dispensing opening, moves the movable wall to the dispensing opening side, and dispenses the medicament into a digestive tract.

Description

技術分野  Technical field
[0001] 本発明は一般に投薬装置、より詳細にはカプセル型投薬装置に関するものである 背景技術  [0001] The present invention relates generally to a dosing device, and more particularly to a capsule-type dosing device.
[0002] そのようなカプセル型投薬装置は、既に提案されている。例えば、 2005年 7月 14 日発行の日本国特許出願公開番号 2005— 185567は、医療用カプセル装置を開 示する。この装置は、本体ユニット及び薬剤ユニットを備える。本体ユニットは、消化 管の内部を観察するための観察手段、外部装置に又はから信号を送受信するため の通信手段、及び通信手段からの信号を受けて薬剤放出動作を制御するための薬 剤放出制御手段を備える。薬剤ユニットは、薬剤を収容し、薬剤を噴射するための噴 射ノズル及び噴射ノズルを開又は閉するための開閉手段を備える。開閉手段は、消 化管内で溶解される溶解性膜力 作られる。  [0002] Such a capsule-type dispensing device has already been proposed. For example, Japanese Patent Application Publication No. 2005-185567, issued July 14, 2005, discloses a medical capsule device. This apparatus includes a main unit and a drug unit. The main unit is an observation means for observing the inside of the digestive tract, a communication means for transmitting / receiving a signal to / from an external device, and a drug release for receiving a signal from the communication means to control a drug release operation. Control means are provided. The medicine unit is provided with an injection nozzle for containing the medicine and injecting the medicine, and an opening / closing means for opening or closing the injection nozzle. The opening and closing means is made of a soluble membrane that dissolves in the extinguishing tube.
[0003] この医療用カプセル装置が消化管内に投与されると、開閉手段、即ち溶解性膜が 徐々に溶解を開始し、やがて噴出ノズルが開成される。そして、モニタ装置に表示さ れる画像を見ながら、操作者は、該装置が所望の部位に到達するまで待機する。該 装置が所望の部位に到達したとき、操作者は、本体ユニットに制御信号を伝送する。 装置は、制御信号を受けて、噴射ノズルを通じて薬剤を消化管内に噴射する。  [0003] When this medical capsule device is administered into the digestive tract, the opening / closing means, that is, the soluble film, gradually starts to dissolve, and the ejection nozzle is eventually opened. Then, while watching the image displayed on the monitor device, the operator waits until the device reaches a desired part. When the device reaches a desired site, the operator transmits a control signal to the main unit. The device receives the control signal and injects the drug into the digestive tract through the injection nozzle.
[0004] 溶解性膜が溶解されて噴出ノズルが開成されるまでの時間は、個人間で異なる。例 えば、装置が所望の部位に到達する前に溶解性膜が溶解されると、薬剤が薬剤ュニ ットから漏れ出すことがある。逆に、装置が所望の部位に到達したときに溶解性膜が 完全に溶解されなければ、全ての薬剤が所望の部位に投与されな!/、可能性がある。 発明の開示  [0004] The time from when the soluble film is dissolved until the ejection nozzle is opened varies among individuals. For example, if the soluble membrane is dissolved before the device reaches the desired site, the drug may leak out of the drug unit. Conversely, if the dissolvable membrane is not completely dissolved when the device reaches the desired site, it is possible that not all of the drug is administered to the desired site! Disclosure of the invention
[0005] 本発明の目的は、消化管内の所望の部位に薬剤を確実に投与することにある。  [0005] An object of the present invention is to reliably administer a drug to a desired site in the digestive tract.
[0006] 本発明のカプセル型投薬装置は、消化管内に投与されるカプセル、投薬開口を持 ちカプセルの一端側内に形成される収納スペース、収納スペース内に格納される薬 剤、及び投薬開口を塞ぐ栓を備える。本発明の第 1特徴に従って、該装置は、可動 壁及び駆動システムを更に備える。可動壁は、収納スペース内に移動自在に置かれ て、収納スペースを第 1スペースと第 2スペースとに仕切るように形成される。第 1スぺ ースは、投薬開口を含み、薬剤を格納するように形成される。駆動システムは、投薬 指令に従って、栓を投薬開口から外し、また可動壁を投薬開口側に移動させて薬剤 を消化管内に投与するように構成される。本発明では、消化管内の所望の部位に薬 剤を確実に投与することができる。 [0006] The capsule-type dosing device of the present invention includes a capsule to be administered into the digestive tract, a storage space having a medication opening and formed on one end side of the capsule, and a medicine stored in the storage space Agents and plugs that plug the dosing opening. According to a first feature of the invention, the apparatus further comprises a movable wall and a drive system. The movable wall is movably placed in the storage space and is formed so as to partition the storage space into a first space and a second space. The first space includes a medication opening and is configured to store a medication. The drive system is configured to remove the stopper from the dosing opening and move the movable wall toward the dosing opening to dispense the drug into the gastrointestinal tract in accordance with a dosing command. In the present invention, the drug can be reliably administered to a desired site in the digestive tract.
[0007] 本発明の第 2特徴に従って、可動壁は永久磁石から構成される。加えて、駆動シス テムは、一対のスパイラル 'コイル及び励磁回路を備える。該スパイラル 'コイルは、そ れぞれ、収納スペースを囲む壁のうち、可動壁の両面に対向する両壁に形成される 。励磁回路は、投薬指令に従って可動壁を投薬開口側に移動させるようにスパイラ ノレ'コイルの各々に給電するように構成される。本発明は、該コイルの各磁場によって 投薬開口側に可動壁を移動させることができるので、栓が投薬開口から外された後、 薬剤を消化管内に投与することができる。 [0007] According to a second aspect of the present invention, the movable wall is made of a permanent magnet. In addition, the drive system includes a pair of spiral coils and an excitation circuit. Each of the spiral coils is formed on both walls of the wall surrounding the storage space facing both sides of the movable wall. The excitation circuit is configured to supply power to each of the spiral coil so as to move the movable wall toward the medication opening in accordance with the medication command. In the present invention, the movable wall can be moved toward the dosing opening by each magnetic field of the coil, so that the drug can be administered into the digestive tract after the stopper is removed from the dosing opening.
[0008] 一実施形態にお!/、て、栓は、遊動嵌合によって投薬開口を塞ぐ。加えて、駆動シス テムは、可動壁を投薬開口側に移動させながら、栓を投薬開口から外して薬剤を消 化管内に投与するように構成される。本実施形態では、可動壁が投薬開口側に移動 して、第 1スペース内の圧力が増大されるので、栓が投薬開口から押し出される。そ の結果、投薬開口が開成され、第 1スペース内の薬剤が投薬開口を通じて消化管内 に投与される。従って、該装置が所望の部位に到達する前に栓が外れるので防止す ることができるので、薬剤が所望の部位に到着する前に漏れ出すのを防止することが できる。しかも、栓は投薬指令に従って投薬開口から外されるので、薬剤をスムーズ に消化管内に投与することができる。 [0008] In one embodiment, the stopper plugs the dosing opening by a loose fit. In addition, the drive system is configured to dispense the drug into the extinguishing tube by moving the movable wall toward the dosing opening and removing the stopper from the dosing opening. In the present embodiment, the movable wall moves toward the medication opening and the pressure in the first space is increased, so that the stopper is pushed out of the medication opening. As a result, the medication opening is opened, and the drug in the first space is administered into the digestive tract through the medication opening. Accordingly, since the stopper is removed before the device reaches the desired site, it can be prevented, so that it is possible to prevent the medicine from leaking out before reaching the desired site. Moreover, since the stopper is removed from the dosing opening according to the dosing instruction, the drug can be smoothly administered into the digestive tract.
[0009] 一実施形態において、栓は、消化管内の温度よりも高い融点で溶融される材料か ら作られる。加えて、駆動システムは、投薬開口側のスパイラル 'コイルのジュール熱 で栓を溶融させることにより栓を投薬開口力 外し、続いて薬剤を消化管内に投与す るように構成される。本実施形態では、栓が投薬開口側のコイルのジュール熱で溶融 されるので、投薬開口への栓の嵌合を緩めることができる。それ故に、栓を外れやす くすること力 Sできる。また、栓を投薬開口に強く嵌合させることができるので、薬剤が栓 と投薬開口との間の隙間から漏れ出るのを抑制することができる。 [0009] In one embodiment, the plug is made from a material that is melted at a melting point that is higher than the temperature in the digestive tract. In addition, the drive system is configured to release the plug opening force by melting the plug with the Joule heat of the spiral opening coil on the drug opening side, and subsequently dispense the drug into the gastrointestinal tract. In this embodiment, since the stopper is melted by Joule heat of the coil on the side of the medication opening, the fitting of the stopper to the medication opening can be loosened. Therefore, it is easy to remove the stopper I can do it. In addition, since the stopper can be strongly fitted into the medication opening, it is possible to prevent the medicine from leaking from the gap between the stopper and the medication opening.
[0010] 本発明の第 3特徴に従って、該装置は、消化管内の温度よりも高い融点で溶融さ れる可溶融膜から作られ、第 2スペースを複数の作動薬室に仕切る可溶融壁を更に 備える。加えて、駆動システムは、各種作動薬、ヒータ及びヒータ駆動回路を備える。 各種作動薬は、作動薬室にそれぞれ格納され、混合されることで体積が膨張する。ヒ ータは、収納スペースを囲む壁に形成される。ヒータ駆動回路は、投薬指令に従って ヒータに給電するように構成される。本発明では、ヒータ駆動回路がヒータに給電する と、ヒータが収納スペース内の可溶融壁を加熱するので、可溶融壁が溶融される。そ の結果、各種作動薬は、混合されて体積が膨張する。従って、各種作動薬の膨張に よって投薬開口側に可動壁を移動させることができるので、栓が投薬開口から外され た後、薬剤を消化管内に投与することができる。  [0010] According to the third aspect of the present invention, the apparatus further comprises a meltable wall made of a meltable film that is melted at a melting point higher than the temperature in the digestive tract, and that partitions the second space into a plurality of working chemical chambers. Prepare. In addition, the drive system includes various types of agonists, a heater, and a heater drive circuit. Each type of agonist is stored in the agonist chamber and mixed to expand the volume. The heater is formed on the wall surrounding the storage space. The heater drive circuit is configured to supply power to the heater in accordance with a medication instruction. In the present invention, when the heater driving circuit supplies power to the heater, the heater heats the meltable wall in the storage space, so that the meltable wall is melted. As a result, various agonists are mixed and expand in volume. Therefore, since the movable wall can be moved to the dosing opening side by the expansion of various agonists, the drug can be administered into the digestive tract after the stopper is removed from the dosing opening.
[0011] 第 3特徴を持つ発明の一実施形態において、栓は、遊動嵌合によって投薬開口を 塞ぐ。加えて、駆動システムは、可動壁を投薬開口側に移動させながら、栓を投薬開 ロカ 外して薬剤を消化管内に投与するように構成される。本実施形態では、可動 壁が各種作動薬の膨張によって投薬開口側に移動するとき、第 1スペース内の圧力 が増大されて、栓が投薬開口から押し出される。その結果、投薬開口が開成され、第 1スペース内の薬剤が投薬開口を通じて消化管内に投与される。従って、該装置が 所望の部位に到達する前に栓が外れるので防止することができるので、薬剤が所望 の部位に到着する前に漏れ出すのを防止することができる。しかも、栓は投薬指令に 従って投薬開口力も外されるので、薬剤を確実に消化管内に投与することができる。  [0011] In an embodiment of the invention having the third feature, the stopper closes the medication opening by a loose fit. In addition, the drive system is configured to dispense the plug into the gastrointestinal tract while moving the movable wall toward the dosing opening and removing the stopper from the dosing lock. In this embodiment, when the movable wall moves to the side of the medication opening due to the expansion of various types of agonist, the pressure in the first space is increased and the stopper is pushed out of the medication opening. As a result, the medication opening is opened, and the drug in the first space is administered into the digestive tract through the medication opening. Accordingly, since the stopper is removed before the device reaches the desired site, it is possible to prevent the device from leaking before reaching the desired site. In addition, since the opening force of the plug is also released in accordance with the medication command, the drug can be reliably administered into the digestive tract.
[0012] 加えて、栓は、前記融点で溶融される材料から作られてもよ!/、。この場合、栓の表 面がヒータによって溶融されると、栓と投薬開口との間の隙間が大きくなるので、栓を 外れやすくすることができる。その結果、薬剤を所望の部位に確実に投与することが できる。 [0012] In addition, the plug may be made from a material that is melted at the melting point! /. In this case, when the surface of the stopper is melted by the heater, the gap between the stopper and the medication opening is increased, so that the stopper can be easily removed. As a result, the drug can be reliably administered to a desired site.
[0013] 一実施形態において、該装置は、前記薬剤として複数の薬剤を含む。この場合、 可溶融壁は、第 1スペースをも複数の薬剤室に仕切るように、可動壁を貫通して第 1 スペースに延びるように形成される。また、複数の薬剤は、それぞれ複数の薬剤室に 格納される。本実施形態では、予め分離することが好ましい種々の薬剤をそれぞれ 複数の薬剤室に格納することができ、種々の薬剤を所望の部位に同時に付与するこ とができる。それ故に、様々な薬剤を所望の部位に投与することができる。 [0013] In an embodiment, the device includes a plurality of drugs as the drug. In this case, the meltable wall is formed so as to extend through the movable wall to the first space so that the first space is also divided into a plurality of drug chambers. Also, multiple drugs can be stored in multiple drug rooms. Stored. In the present embodiment, various drugs that are preferably separated in advance can be stored in a plurality of drug chambers, and various drugs can be simultaneously applied to desired sites. Therefore, various drugs can be administered to the desired site.
[0014] 一実施形態において、栓及び可溶融壁は、牛脂から作られ互いに一体化される。 [0014] In one embodiment, the stopper and the meltable wall are made from beef tallow and are integrated with each other.
本実施形態では、可溶融壁が溶融されるとき、栓もまた溶融されるので、投薬開口を 確実に開口して薬剤を消化管内にスムーズに投与することができる。しかも、栓及び 可溶融壁が、融点が 40— 45°Cである牛脂から作られるので、消化管内の温度下で は溶融し難い。また、栓及び可溶融壁が溶融されて被験者の体内に吸収されても、 それらは健康に害はない。  In this embodiment, when the meltable wall is melted, the stopper is also melted, so that the medication opening can be reliably opened and the drug can be smoothly administered into the digestive tract. Moreover, since the stopper and the meltable wall are made of beef tallow with a melting point of 40-45 ° C, it is difficult to melt at temperatures in the digestive tract. In addition, even if the stopper and meltable wall are melted and absorbed into the subject's body, they are not harmful to health.
図面の簡単な説明  Brief Description of Drawings
[0015] 本発明の好ましい実施形態をさらに詳細に記述する。本発明の他の特徴および利 点は、以下の詳細な記述および添付図面に関連して一層良く理解されるものである  [0015] Preferred embodiments of the invention are described in further detail. Other features and advantages of the present invention will be better understood with reference to the following detailed description and accompanying drawings.
[図 1]本発明の第 1実施形態によるカプセル型投薬装置の概要縦断面図である。 FIG. 1 is a schematic longitudinal sectional view of a capsule dosing device according to a first embodiment of the present invention.
[図 2]投薬後の該投薬装置の概要縦断面図である。  FIG. 2 is a schematic longitudinal sectional view of the dosing device after dosing.
[図 3]該投薬装置のコイルの概要図である。  FIG. 3 is a schematic view of a coil of the dosing device.
[図 4]該投薬装置の各コイルの製造技術のフロー図である。  FIG. 4 is a flow diagram of manufacturing technology for each coil of the dosing device.
[図 5]図 5A—Cは該製造技術の各工程における MIDの斜視図である。  [FIG. 5] FIGS. 5A to 5C are perspective views of the MID in each process of the manufacturing technique.
[図 6]図 6A及び Bは該製造技術の各工程における MIDの斜視図である。  FIG. 6A and FIG. 6B are perspective views of MID in each process of the manufacturing technique.
[図 7]本発明の第 2実施形態によるカプセル型投薬装置の概要縦断面図である。  FIG. 7 is a schematic longitudinal sectional view of a capsule dosing device according to a second embodiment of the present invention.
[図 8]投薬後の該投薬装置の概要縦断面図である。  FIG. 8 is a schematic longitudinal sectional view of the dosing device after dosing.
[図 9]該投薬装置のヒータの概要図である。  FIG. 9 is a schematic view of a heater of the dosing device.
発明を実施するための最良の形態  BEST MODE FOR CARRYING OUT THE INVENTION
[0016] 図 1は、本発明の第 1実施形態によるカプセル型投薬装置 Aを示す。このカプセル 型投薬装置 Aは、例えばセラミック又はポリエーテルエーテルケトン (PEEK)等の耐 熱性材料から形成されたカプセル 1を備えている。カプセル 1は、例えば長円体形又 はシリンダ形状等に形成される。図 1の例では、カプセル 1はシリンダ形状である。  [0016] FIG. 1 shows a capsule-type dispensing device A according to a first embodiment of the present invention. The capsule-type dosing device A includes a capsule 1 made of a heat resistant material such as ceramic or polyetheretherketone (PEEK). The capsule 1 is formed, for example, in an oval shape or a cylinder shape. In the example of FIG. 1, the capsule 1 has a cylindrical shape.
[0017] カプセル 1の内部は、軸方向（縦方向）の中間部に配置された固定壁 2によって左 右の収容スペース 3及び 4に仕切られている。左の収容スペース 3は可動壁 5が具備 される。可動壁 5は、収容スペース 3の横断面よりもやや小さい平面形状の永久磁石 から構成され、軸方向に自由に動くように収容スペース 3内に置かれる。 [0017] The inside of the capsule 1 is left by a fixed wall 2 arranged in the middle part in the axial direction (vertical direction) Divided into right storage spaces 3 and 4. The left accommodation space 3 is provided with a movable wall 5. The movable wall 5 is composed of a planar permanent magnet that is slightly smaller than the cross section of the accommodation space 3, and is placed in the accommodation space 3 so as to move freely in the axial direction.
[0018] ここで、投与される薬剤 8を収容するための第 1スペース 3aは、収容スペース 3の左 の端面と可動壁 5に挟まれたスペースから形成されている。また、カプセル 1の左端 には、第 1スペース 3aを外部に開放するための投薬開口 6 (例えばスルーホール）が 形成されている。この投薬開口 6は、遊動嵌合（隙間嵌）によって外側から栓 7で塞が れる。栓 7は、消化管内の温度よりも高い融点（例えば 40— 45°C)で溶融される材料 (例えば牛脂等）から作られる。カプセル 1には、更に、可動壁 5と固定壁 2の間のス ペースを外部に開放するための通気孔（図示せず）が形成されて!/、る。  [0018] Here, the first space 3a for accommodating the medicine 8 to be administered is formed of a space sandwiched between the left end face of the accommodation space 3 and the movable wall 5. In addition, a medication opening 6 (for example, a through hole) for opening the first space 3a to the outside is formed at the left end of the capsule 1. The dosing opening 6 is closed from the outside with a stopper 7 by loose fitting (gap fitting). The plug 7 is made of a material (eg, beef tallow) that is melted at a melting point (eg, 40-45 ° C) higher than the temperature in the digestive tract. The capsule 1 is further formed with a vent hole (not shown) for opening the space between the movable wall 5 and the fixed wall 2 to the outside!
[0019] 固定壁 2における収容スペース 4側の表面 2a及びカプセル 1の左端の内面 laには 、それぞれ、 MID (molded interconnect device)製造技術によって一対のスパイラノレ' コイル 9及び 10が形成されている。該製造技術については後述する。  [0019] A pair of spiral coil coils 9 and 10 are formed on the surface 2a on the side of the accommodation space 4 in the fixed wall 2 and the inner surface la of the left end of the capsule 1 by a MID (molded interconnect device) manufacturing technique, respectively. The manufacturing technique will be described later.
[0020] 図 3は、固定壁 2の表面 2aに形成されたコイル 9の概要図である。スパイラル'コィ ル 9の外側端部は、後述のバッテリ 34と接続される端子 9aである。スパイラル.コイル 9の内側の端部は、スルーホール 2bを介して裏面に形成された導電パターン 11に電 気的に接続されている。この導電パターン 11は、軸方向に収容スペース 3の頂部に 形成された金属めつき層である導電ライン 12の一端に電気的に接続されている。導 電ライン 12の他端は、カプセル 1の左端の外面に形成された導電パターン 13と、該 左端に形成されたスルーホール lbを介して、電気的に接続されている。導電パター ン 13は、カプセル 1の左端の外面において外縁から中心側に形成されている。該中 心側での導電パターン 13の端部は、該左端に形成されたスルーホール lcを介して、 該左端の内面 laに形成されたスパイラル 'コイル 10の内部端と電気的に接続されて いる。スパイラル 'コイル 10の外部端は、軸方向に収容スペース 3の底部に形成され た金属めつき層である導電ライン 14と接続されている。固定壁 2の表面 2aには、導電 ライン 14と電気的に接続される端子 15が形成されている。つまり、スパイラル 'コイル 9及び 10が、端子 15及び 9aの間に直列に接続されているのである。カプセル 1外面 の導電パターン 13は、絶縁層（図示しない）で覆われており、絶縁が確保されている [0021] 収容スペース 4は、投薬指令（トリガ入力）に従って投薬動作を行うための制御回路 30を格納する。制御回路 30は、励磁回路 31、通信回路 32及びカメラ 35を備える。 励磁回路 31は、バッテリ 34を介して端子 9a及び 15間に接続されるスィッチ素子（図 示せず）を有し、スパイラル 'コイル 9及び 10への電力供給をオン/オフするように該 スィッチ素子のオン/オフを制御するように構成される。通信回路 32は、アンテナ 33 を介して、被験者の体外に配置された遠隔操作システム（図示せず）に又はから電波 信号を送受信するように構成される。カメラ 35は、カプセル 1の外部の画像、即ち被 験者の消化管内の画像をとるように構成される。詳しくは、通信回路 32は、指定時間 間隔毎にカメラ 35を通じてとられた画像データを含む電波信号を該遠隔操作システ ムに送信する。また、該遠隔操作システムからの投薬指令を含む電波信号を受信す ると、通信回路 32は、該投薬指令を励磁回路 31に与える。該通信回路 32から投薬 指令を受けると、励磁回路 31は、該スィッチ素子をオンして、バッテリ 34の DC (直流 )電圧をスパイラル 'コイル 9及び 10に印加する。これにより、スパイラル 'コイル 9及び 10の各々は磁界を発生する。ここで、スパイラル 'コイル 9の巻き及び励磁電流の方 向は、スパイラル 'コイル 9が可動壁 5を反発するための磁界を発生するように設定さ れる。スパイラル 'コイル 10の巻き及び励磁電流の方向は、スパイラル 'コイル 10が可 動壁 5を吸引するための磁界を発生するように設定される。従って、収納スペース 3内 の可動壁 5は、スパイラル 'コイル 9及び 10の磁界によって、固定壁 2側から投薬開口 6側に移動される。 FIG. 3 is a schematic diagram of the coil 9 formed on the surface 2 a of the fixed wall 2. The outer end of the spiral coil 9 is a terminal 9a connected to a battery 34 described later. The inner end of the spiral coil 9 is electrically connected to the conductive pattern 11 formed on the back surface through the through hole 2b. The conductive pattern 11 is electrically connected to one end of a conductive line 12 which is a metal plating layer formed on the top of the accommodation space 3 in the axial direction. The other end of the conductive line 12 is electrically connected to a conductive pattern 13 formed on the outer surface of the left end of the capsule 1 via a through hole lb formed on the left end. The conductive pattern 13 is formed on the outer surface of the left end of the capsule 1 from the outer edge to the center side. The end of the conductive pattern 13 on the center side is electrically connected to the inner end of the spiral coil 10 formed on the inner surface la of the left end through a through hole lc formed on the left end. Yes. The outer end of the spiral coil 10 is connected to a conductive line 14 that is a metal plating layer formed on the bottom of the accommodation space 3 in the axial direction. A terminal 15 that is electrically connected to the conductive line 14 is formed on the surface 2 a of the fixed wall 2. That is, the spiral coils 9 and 10 are connected in series between the terminals 15 and 9a. The conductive pattern 13 on the outer surface of the capsule 1 is covered with an insulating layer (not shown) to ensure insulation. The storage space 4 stores a control circuit 30 for performing a medication operation according to a medication command (trigger input). The control circuit 30 includes an excitation circuit 31, a communication circuit 32, and a camera 35. The excitation circuit 31 has a switch element (not shown) connected between the terminals 9a and 15 via the battery 34, and the switch element so as to turn on / off the power supply to the spiral coils 9 and 10. Configured to control on / off of the. The communication circuit 32 is configured to transmit and receive radio signals via an antenna 33 to or from a remote control system (not shown) arranged outside the subject's body. The camera 35 is configured to take an image outside the capsule 1, that is, an image in the subject's digestive tract. Specifically, the communication circuit 32 transmits a radio signal including image data taken through the camera 35 to the remote control system at specified time intervals. In addition, when receiving a radio wave signal including a medication command from the remote operation system, the communication circuit 32 gives the medication command to the excitation circuit 31. When receiving a medication command from the communication circuit 32, the excitation circuit 31 turns on the switch element and applies a DC (direct current) voltage of the battery 34 to the spiral coils 9 and 10. As a result, each of the spiral coils 9 and 10 generates a magnetic field. Here, the direction of the winding of the spiral coil 9 and the excitation current is set so that the spiral coil 9 generates a magnetic field for repelling the movable wall 5. The direction of winding and excitation current of the spiral 'coil 10 is set so that the spiral' coil 10 generates a magnetic field for attracting the movable wall 5. Accordingly, the movable wall 5 in the storage space 3 is moved from the fixed wall 2 side to the medication opening 6 side by the magnetic field of the spiral coils 9 and 10.
[0022] カプセル型投薬装置 Aは、上記のような構成を有して!/、る。次に、カプセル型投薬 装置 A (カプセル 1ともいう）を介した投薬方法について説明する。収容スペース 3内 の可動壁 5は固定壁 2側に配置され、続いて第 1スペース 3aには投薬開口 6から薬 剤が充填される。その後、栓 7が投薬開口 6に嵌着されて該開口が閉塞される（図 1 参照)。  [0022] The capsule-type dosing device A has the above-described configuration! Next, a dosing method via the capsule-type dosing device A (also referred to as capsule 1) will be described. The movable wall 5 in the accommodation space 3 is arranged on the fixed wall 2 side, and then the first space 3a is filled with a medicine from the medication opening 6. Thereafter, the stopper 7 is fitted into the dosing opening 6 and the opening is closed (see FIG. 1).
[0023] 被験者がカプセル 1を嚥下すると、カプセル 1は被験者の消化管内をその蠕動運 動によって移動する。カプセル 1は、その間、指定時間間隔毎にカメラ 35を通じてと られた画像を遠隔操作システムへ送信する。該遠隔操作システムは、カプセル 1から の各画像を該遠隔操作システムのモニタに表示する。それ故に、薬剤担当者 (操作 者）は、カプセル 1の現在位置を把握することができる。該モニタに表示される画像に 基づいて、該薬剤が投与される部位にカプセル 1が到達したことを確認すると、操作 者は、該遠隔操作システムを操作して、投薬指令を含む無線信号を該遠隔操作シス テムからカプセル 1に伝送する。 [0023] When the subject swallows the capsule 1, the capsule 1 moves in the digestive tract of the subject by its peristaltic movement. In the meantime, the capsule 1 transmits images taken through the camera 35 to the remote control system at specified time intervals. The remote control system starts from capsule 1 Are displayed on the monitor of the remote control system. Therefore, the person in charge of medicine (operator) can grasp the current position of the capsule 1. When it is confirmed that the capsule 1 has reached the site where the medicine is administered based on the image displayed on the monitor, the operator operates the remote control system to send a radio signal including a medication command. Transmit to capsule 1 from the remote control system.
[0024] カプセル 1にお!/、て、通信回路 32が投薬指令を受信すると、該投薬指令は励磁回 路 31に与えられる。励磁回路 31は、前記スィッチ素子をオンして、ノ ッテリ 34の DC 電圧をスパイラル 'コイル 9及び 10に印加する。それ故に、スパイラル 'コイル 9は可 動壁 5を反発するための磁界を発生する一方、スパイラル 'コイル 10は可動壁 5を吸 引するための磁界を発生する。要するに、スパイラル 'コイル 9及び 10の各々は、可 動壁 5を投薬開口 6側に移動させるための磁力を発生する。  When the communication circuit 32 receives the medication command for the capsule 1! /, The medication command is given to the excitation circuit 31. The excitation circuit 31 turns on the switch element and applies the DC voltage of the notch 34 to the spiral coils 9 and 10. Therefore, the spiral 'coil 9 generates a magnetic field for repelling the movable wall 5, while the spiral' coil 10 generates a magnetic field for attracting the movable wall 5. In short, each of the spiral coils 9 and 10 generates a magnetic force for moving the movable wall 5 toward the dosing opening 6 side.
[0025] 可動壁 5が各磁力によって投薬開口 6側に移動しょうとすると、第 1スペース 3a内に 格納された薬剤 8が圧縮されて、該第 1スペース 3a内の圧力が上昇する。遊動嵌合 によって投薬開口 6を塞ぐ栓 7が該圧力上昇で押し出されて、投薬開口 6が開放され る。その後、可動壁 5が投薬開口 6近くに移動し、第 1スペース 3a内の薬剤 8が、その 間、投薬開口 6から押し出されて消化管内の所望の部位に投与される（図 2参照)。こ こで、栓 7は、投薬開口 6周りのスパイラル 'コイル 10のジュール熱で溶融可能な牛脂 (融点 =40— 45°C)などの材料から作られるので、栓 7の表面は、スパイラル.コイル 10に給電した後に溶融される。これにより、投薬開口 6と栓 7との間の嵌合が緩くなる ので、栓 7を外れ易くできる。従って、栓 7を投薬開口 6に強く嵌合させることができ、 薬剤 8が栓 7と投薬開口 6との間の隙間から漏れ出るのを抑制することができる。  [0025] When the movable wall 5 tries to move toward the dosing opening 6 side by each magnetic force, the medicine 8 stored in the first space 3a is compressed, and the pressure in the first space 3a increases. The plug 7 that closes the dosing opening 6 by the loose fitting is pushed out by the pressure increase, and the dosing opening 6 is opened. Thereafter, the movable wall 5 moves near the dosing opening 6, and the drug 8 in the first space 3a is pushed out of the dosing opening 6 and administered to a desired site in the digestive tract (see FIG. 2). Here, the plug 7 is made of a material such as a beef tallow (melting point = 40-45 ° C) that can be melted by spiral heat around the dosing opening 6 'coil 10', so the surface of the plug 7 is spiral. After the coil 10 is powered, it is melted. Thereby, since the fitting between the medication opening 6 and the stopper 7 becomes loose, the stopper 7 can be easily detached. Therefore, the stopper 7 can be strongly fitted into the medication opening 6, and the medicine 8 can be prevented from leaking from the gap between the stopper 7 and the medication opening 6.
[0026] 第 1実施形態では、操作者が遠隔操作システムを通じて投薬指令を送信したときに 、カプセル型投薬装置 Aがスパイラル 'コイル 9及び 10に給電して可動壁 5を移動さ せる結果、栓 7が投薬開口 6から押し出されて薬剤 8が消化管内に投与される。この ように、投薬のタイミングのばらつきを低減して、投薬のタイミングを厳密に制御すれ ば、薬剤を所望の部位に確実に投与することができる。また、可動壁 5をスパイラル' コイル 9及び 10の磁界で駆動するので、可動壁 5をほぼ一定の力で駆動することが でき、薬剤 8をほぼ一定の流速で投薬開口 6から放出することができる。 [0027] さて、図 4、 5A— 5C、及び 6A及び 6Bを参照して、コイル 9及び 10を形成するのに 使用される MID製造技術について説明する。図 4は、 MID製造技術の概要フロー 図である。 MIDは、 [0026] In the first embodiment, when the operator transmits a medication command through the remote control system, the capsule-type medication device A feeds the spiral coils 9 and 10 and moves the movable wall 5 as a result. 7 is pushed out of the dosing opening 6 and the drug 8 is administered into the gastrointestinal tract. As described above, if the timing of dosing is strictly controlled by reducing variation in dosing timing, the drug can be reliably administered to a desired site. Further, since the movable wall 5 is driven by the magnetic field of the spiral coils 9 and 10, the movable wall 5 can be driven with a substantially constant force, and the drug 8 can be released from the dosing opening 6 at a substantially constant flow rate. it can. Now, with reference to FIGS. 4, 5A-5C, and 6A and 6B, the MID manufacturing technique used to form the coils 9 and 10 will be described. Figure 4 is a schematic flow diagram of MID manufacturing technology. MID is
(51)樹脂材料の射出成型を通じて所望の MID21を成型する成型工程；  (51) Molding process for molding desired MID21 through injection molding of resin material;
(52)スパッタリング、蒸着又はイオンプレーティング等の物理蒸着（PVD)法によつ て MID21の表面に導電性薄膜 22を形成するメタライズ処理工程；  (52) a metallization process for forming a conductive thin film 22 on the surface of MID21 by a physical vapor deposition (PVD) method such as sputtering, vapor deposition or ion plating;
(53)高エネルギービーム（例えばレーザビーム）で回路部及び非回路部を分離する レーザ処理工程；  (53) A laser processing step of separating the circuit portion and the non-circuit portion with a high energy beam (for example, a laser beam);
(54)回路部に厚膜めつき層 23を形成するめつき処理工程;及び  (54) a plating process for forming a thick film adhesive layer 23 in the circuit portion; and
(S 5)非回路部のエッチング処理工程；  (S 5) Non-circuit portion etching process;
を順次実施することで製造される。  Are manufactured sequentially.
[0028] 図 5A— 5C、及び 6A及び 6Bは、図 4の各工程における MID (C)の表面処理状態 を示す。図 5Aは成型工程（S1)に対応し、所望の三次元形状の MID21が、絶縁合 成樹脂の射出成型を通じて成型される。 MID21の成型材料は、例えば、熱可塑性 樹脂の場合は芳香族ポリアミド又は液晶性ポリエステル等であり、或いは熱硬化性樹 脂の場合はエポキシ樹脂又は飽和ポリエステル等である。セラミックの場合は窒化ァ ノレミナ等が用いられる。なお、射出成形に限らず、 MID21の成型方法は、押出成型 又はトランスファ成型等でもよ!/、。  [0028] FIGS. 5A-5C and 6A and 6B show the surface treatment states of MID (C) in each step of FIG. FIG. 5A corresponds to the molding step (S1), and a desired three-dimensional MID 21 is molded through injection molding of an insulating synthetic resin. The molding material of MID21 is, for example, aromatic polyamide or liquid crystalline polyester in the case of a thermoplastic resin, or epoxy resin or saturated polyester in the case of a thermosetting resin. In the case of ceramic, nitride anolemina is used. Not limited to injection molding, the molding method of MID21 may be extrusion molding or transfer molding!
[0029] 図 5Bはメタライズ処理工程（S2)に対応し、導電性薄膜 22は、例えば銅ターゲット のスパッタリング、真空蒸着又はイオンプレーティング等の PVD法によって、 MID21 の表面に形成される。なお、 PVD法に限らず、化学蒸着法等を使用してもよい。導 電性薄膜 22の材料は、ニッケル、金、アルミニウム、チタン、モリブデン、クロム、タン ダステン、スズ又は鉛等の単体金属、又は黄銅又は NiCr等の合金でもよい。  FIG. 5B corresponds to the metallization process (S2), and the conductive thin film 22 is formed on the surface of the MID 21 by a PVD method such as sputtering, vacuum deposition or ion plating of a copper target, for example. Note that not only the PVD method but also a chemical vapor deposition method may be used. The material of the conductive thin film 22 may be a single metal such as nickel, gold, aluminum, titanium, molybdenum, chromium, tantasten, tin or lead, or an alloy such as brass or NiCr.
[0030] 図 5Cはレーザ処理工程（S3)に対応する。高エネルギービーム、例えばレーザビ ーム（電磁波ビーム） 1S 導電性薄膜 22における回路部 23a及び非回路部 23bの境 界部分に照射され、境界部分の導電性薄膜が蒸発及び除去される。回路部 23a及 び非回路部 23bはその除去部 23cで分離され、所望の回路パターンが形成される。  FIG. 5C corresponds to the laser processing step (S3). A high energy beam, for example, a laser beam (electromagnetic beam) is irradiated on the boundary portion of the circuit portion 23a and the non-circuit portion 23b in the 1S conductive thin film 22, and the conductive thin film at the boundary portion is evaporated and removed. The circuit portion 23a and the non-circuit portion 23b are separated by the removal portion 23c, and a desired circuit pattern is formed.
[0031] 図 6Aはめつき処理工程（S4)に対応する。回路部 23aの各々は、電流を供給され て例えば電解銅めつきの厚膜で覆われ、めっき層 24が形成される。非回路部 23bの 各々は電流を供給されないので、非回路部 23bの各膜厚は変化しない。 FIG. 6A corresponds to the fitting process step (S4). Each of the circuit parts 23a is supplied with current. For example, the plated layer 24 is formed by covering with a thick film of electrolytic copper plating. Since each non-circuit portion 23b is not supplied with current, the thickness of each non-circuit portion 23b does not change.
[0032] 図 6Bはエッチング処理工程（S5)に対応する。 MID21の全回路パターンがエッチ ングされ、非回路部 23bが除去される。これにより、回路パターンが形成された MID が得られる。スパイラル 'コイル 9及び 10は、そのような製造技術によって形成すること ができる。 FIG. 6B corresponds to the etching process (S5). The entire circuit pattern of MID21 is etched, and the non-circuit portion 23b is removed. As a result, the MID on which the circuit pattern is formed is obtained. Spiral coils 9 and 10 can be formed by such manufacturing techniques.
[0033] 図 7は、本発明の第 2実施形態によるカプセル型投薬装置 Bを示す。明瞭のため、 同様の要素には、第 1実施形態で表されたのと同じ符号が割り当てられる。カプセル 型投薬装置 Bは、例えばセラミック又は PEEK等の耐熱性材料から形成されたカブ セル 1を備えている。カプセル 1は、例えば長円体形又はシリンダ形状等に形成され る。図 7の例では、カプセル 1はシリンダ形状である。  [0033] FIG. 7 shows a capsule dosing device B according to a second embodiment of the present invention. For the sake of clarity, similar elements are assigned the same reference signs as in the first embodiment. The capsule-type dosing device B includes a capsule 1 made of a heat resistant material such as ceramic or PEEK. The capsule 1 is formed, for example, in an oval shape or a cylinder shape. In the example of FIG. 7, the capsule 1 has a cylinder shape.
[0034] カプセル 1の内部は、軸方向（縦方向）の中間部に配置された固定壁 2によって左 右の収容スペース 3及び 4に仕切られている。左の収容スペース 3は可動壁 5が具備 される。可動壁 5は、軸方向に自由に動くように収容スペース 3内に置かれ、該収容 スペース 3を第 1 (左側）スペース 3a及び第 2 (右側）スペース 3bに仕切ることができる 。第 1スペース 3aは複数の薬剤を収納する。第 2スペース 3bは、混合されることで体 積が膨張する各種作動薬を格納する。  [0034] The inside of the capsule 1 is partitioned into left and right accommodation spaces 3 and 4 by a fixed wall 2 disposed in an intermediate portion in the axial direction (vertical direction). The left accommodation space 3 is provided with a movable wall 5. The movable wall 5 is placed in the accommodation space 3 so as to move freely in the axial direction, and the accommodation space 3 can be partitioned into a first (left side) space 3a and a second (right side) space 3b. The first space 3a stores a plurality of medicines. The second space 3b stores various agonists whose volume is expanded by being mixed.
[0035] カプセル 1の左端には、第 1スペース 3aを外部に開放するためのスリットである投薬 開口 6が形成されている。可動壁 5には、投薬開口 6に対応する位置に配置されて該 可動壁 5の厚み方向に該可動壁 5を突き抜けるスルーホール 5aが形成されて!/、る。  [0035] At the left end of the capsule 1, a medication opening 6 which is a slit for opening the first space 3a to the outside is formed. The movable wall 5 is formed with a through hole 5a which is disposed at a position corresponding to the medication opening 6 and penetrates the movable wall 5 in the thickness direction of the movable wall 5! /.
[0036] 収納スペース 3には、その中に可溶融壁 7Aが具備される。可溶融壁 7Aは、消化管 内の温度よりも高!/、融点（例えば 40— 45°C)で溶融される可溶融膜 (例えば牛脂等） 力、ら作られる。この可溶融壁 7Aは、投薬開口 6及びスルーホール 5aに揷入され、第 1スペース 3aを上薬剤室 3a_l及び下薬剤室 3a_2に仕切り、また第 2スペース 3bを上 作動薬室 3b_l及び下作動薬室 3b_2に仕切る。可溶融壁 7Aの先端には投薬開口 6 力、ら突き出て投薬開口 6を塞ぐ栓 7が形成され、この栓 7は、該可溶融壁 7Aの残部よ りも厚みが大きくなるように形成される。  [0036] The storage space 3 is provided with a meltable wall 7A therein. The meltable wall 7A is made of a meltable film (eg, beef tallow) that is melted at a melting point (eg, 40-45 ° C) higher than the temperature in the digestive tract! This meltable wall 7A is inserted into the dosing opening 6 and the through hole 5a, partitions the first space 3a into the upper drug chamber 3a_l and the lower drug chamber 3a_2, and operates the second space 3b as the upper drug chamber 3b_l and the lower drug chamber. Partition into chamber 3b_2. A plug 7 is formed at the tip of the meltable wall 7A so as to protrude from the dosing opening 6 and close the dosing opening 6. The plug 7 is formed to have a thickness larger than the remaining part of the meltable wall 7A. The
[0037] このように薬剤室 3a_l及び 3a_2を設けることにより、 2種類の薬剤 8a及び 8bを分離 して該室 3a_l及び 3a_2にそれぞれ格納することができる。同様に、作動薬室 3b_l 及び 3b_2が設けられるので、混合されることで体積が膨張する 2種類の作動薬 19a 及び 19bを分離して該作動薬室 3b_l及び 3b_2にそれぞれ格納することができる。こ こで、作動薬 19a及び 19bは、被験者の体内に排出されるので、無害な物質であるこ とが好ましい。例えば、作動薬 19aは好ましくは酢又はレモン汁等の酸であり、作動 薬 19bは好ましくは炭酸水素ナトリウム又はラムネ (lemonade sweets)等である。薬剤 室 3a-l及び 3a-2および作動薬室 3b-l及び 3b-2には、めいめいにスルーホール（ 図示せず）が形成され、それぞれ該スルーホールを介して薬剤 8a及び 8b及び作動 薬 19a及び 19bが充填される。それらが充填された後、各スルーホールは、限定され ないが、特に液体が出入りすることができないように封止される。その結果、薬剤 8a 及び 8b及び作動薬 19a及び 19bがそれぞれ薬剤室 3a_l及び 3a_2および作動薬室 3b_l及び 3b_2に封入される（図 7参照）。 [0037] By thus providing the drug chambers 3a_l and 3a_2, the two types of drugs 8a and 8b are separated. And can be stored in the chambers 3a_l and 3a_2, respectively. Similarly, since the agonist chambers 3b_l and 3b_2 are provided, the two types of agonists 19a and 19b whose volumes expand when mixed can be separated and stored in the agonist chambers 3b_l and 3b_2, respectively. Here, the agonists 19a and 19b are preferably harmless substances because they are excreted into the body of the subject. For example, agonist 19a is preferably an acid such as vinegar or lemon juice, and agonist 19b is preferably sodium bicarbonate or lemonade sweets. The drug chambers 3a-l and 3a-2 and the working drug chambers 3b-l and 3b-2 are formed with through holes (not shown), and the drugs 8a and 8b and the working chemicals are respectively formed through the through holes. 19a and 19b are filled. After they are filled, each through-hole is sealed, particularly but not limited to, liquids can enter and exit. As a result, drugs 8a and 8b and agonists 19a and 19b are sealed in drug chambers 3a_l and 3a_2 and agonist chambers 3b_l and 3b_2, respectively (see FIG. 7).
[0038] カプセル 1の左端の内面 la及び固定壁 2における収容スペース 4側の表面 2aには 、それぞれ上述の MID製造技術によって、一対のコイル状ヒータ 16及び 17が形成さ れる。図 9は、固定壁 2の表面 2aに形成されたコイル状ヒータ 17の概略形状を示す。 コイル状ヒータ 17の一端は、後述のバッテリ 34と接続される端子 17aであり、その他 端は端子 17bであり、それは軸方向に収容スペース 3の頂部に形成された金属めつ き層である導電ライン 12の一端と接続される。収容スペース 3の底部にもまた、軸方 向に形成された金属めつき層である導電ライン 14が形成され、該導電ライン 14の一 端と電気的に接続される端子 15が、固定壁 2の表面 2aに形成されている。導電ライ ン 12及び 14の他端は、それぞれカプセル 1の内面 laに形成されたコイル状ヒータ 1 6の両端と電気的に接続されるので、コイル状ヒータ 16及び 17は端子 17a及び 15間 に直列に接続される。 [0038] A pair of coiled heaters 16 and 17 are formed on the inner surface la of the left end of the capsule 1 and the surface 2a on the accommodation space 4 side of the fixed wall 2 by the MID manufacturing technique described above, respectively. FIG. 9 shows a schematic shape of the coil heater 17 formed on the surface 2 a of the fixed wall 2. One end of the coiled heater 17 is a terminal 17a connected to a battery 34, which will be described later, and the other end is a terminal 17b, which is a conductive metal layer formed on the top of the accommodation space 3 in the axial direction. Connected to one end of line 12. A conductive line 14 which is a metal plating layer formed in the axial direction is also formed at the bottom of the accommodation space 3, and a terminal 15 electrically connected to one end of the conductive line 14 is connected to the fixed wall 2. Formed on the surface 2a. Since the other ends of the conductive lines 12 and 14 are electrically connected to both ends of the coil heater 16 formed on the inner surface la of the capsule 1, respectively, the coil heaters 16 and 17 are connected between the terminals 17a and 15. Connected in series.
[0039] 収容スペース 4は、投薬指令（トリガ入力）に従ってコイル状ヒータ 16及び 17に電力 を供給するための制御回路 30を格納する。制御回路 30は、ヒータ駆動回路 36、通 信回路 32及びカメラ 35を備える。ヒータ駆動回路 36は、バッテリ 34を介して端子 17 a及び 15間に接続されるスイッチング素子（図示せず）を有するスイッチング回路であ り、該スイッチング素子のオン/オフを制御してコイル状ヒータ 16及び 17への供給電 力を制御するように構成される。通信回路 32は、アンテナ 33を介して、被験者の体 外に配置された遠隔操作システム（図示せず）に又はから電波信号を送受信するよう に構成される。カメラ 35は、カプセル 1の外部の画像、即ち被験者の消化管内の画 像をとるように構成される。詳しくは、通信回路 32は、指定時間間隔毎にカメラ 35を 通じてとられた画像データを含む電波信号を該遠隔操作システムに送信する。また、 該遠隔操作システムからの投薬指令 (加熱指令)を含む電波信号を受信すると、通 信回路 32は、該投薬指令をヒータ駆動回路 36に与える。該通信回路 32から投薬指 令を受けると、ヒータ駆動回路 36は、ノ ッテリ 34の DC電圧をスイッチングすることに よって、予め決められた電力をコイル状ヒータ 16及び 17に供給し、それにより、コィ ル状ヒータ 16及び 17に収納スペース 3を前記融点よりも高い予め決められた温度に 加熱させる。 The storage space 4 stores a control circuit 30 for supplying power to the coiled heaters 16 and 17 in accordance with a medication command (trigger input). The control circuit 30 includes a heater drive circuit 36, a communication circuit 32, and a camera 35. The heater driving circuit 36 is a switching circuit having a switching element (not shown) connected between the terminals 17a and 15 via the battery 34, and controls the on / off of the switching element to produce a coiled heater. Power supply to 16 and 17 Configured to control force. The communication circuit 32 is configured to transmit and receive radio signals via an antenna 33 to or from a remote control system (not shown) arranged outside the subject's body. The camera 35 is configured to take an image outside of the capsule 1, that is, an image in the subject's digestive tract. Specifically, the communication circuit 32 transmits a radio signal including image data taken through the camera 35 to the remote control system at specified time intervals. Further, when receiving a radio signal including a medication command (heating command) from the remote operation system, the communication circuit 32 gives the medication command to the heater drive circuit 36. Upon receiving a medication instruction from the communication circuit 32, the heater drive circuit 36 supplies a predetermined power to the coiled heaters 16 and 17 by switching the DC voltage of the battery 34, thereby The storage space 3 is heated by the coil heaters 16 and 17 to a predetermined temperature higher than the melting point.
[0040] カプセル型投薬装置 Bは、上記のような構成を有している。次に、カプセル型投薬 装置 B (カプセル 1ともレ、う）を介した投薬方法につ!/、て説明する。可溶融壁 7Aが投 薬開口 6及びスルーホール 5aに揷入され、第 1スペース 3a及び第 2スペース 3bが薬 剤室 3a_l及び 3a_2及び作動薬室 3b_l及び 3b_2に仕切られる。その状態で、薬剤 室 3a_l及び 3a_2及び作動薬室 3b_l及び 3b_2に、それぞれ薬剤 8a及び 8b及び作 動薬 19a及び 19bが充填される。  [0040] The capsule dosing device B has the above-described configuration. Next, a description will be given of a dosing method via the capsule-type dosing device B (both capsules 1). The meltable wall 7A is inserted into the injection opening 6 and the through hole 5a, and the first space 3a and the second space 3b are partitioned into the chemical chambers 3a_l and 3a_2 and the working chemical chambers 3b_l and 3b_2. In this state, drug chambers 3a_l and 3a_2 and agonist chambers 3b_l and 3b_2 are filled with drugs 8a and 8b and agonists 19a and 19b, respectively.
[0041] 被験者がカプセル 1を嚥下すると、カプセル 1は被験者の消化管内をその蠕動運 動によって移動する。カプセル 1は、その間、指定時間間隔毎にカメラ 35を通じてと られた画像を遠隔操作システムへ送信する。該遠隔操作システムは、カプセル 1から の各画像を該遠隔操作システムのモニタに表示する。それ故に、薬剤担当者 (操作 者）は、カプセル 1の現在位置を把握することができる。該モニタに表示される画像に 基づいて、該薬剤が投与される部位にカプセル 1が到達したことを確認すると、操作 者は、該遠隔操作システムを操作して、投薬指令 (加熱指令)を含む無線信号を該 遠隔操作システム力、らカプセル 1に伝送する。  [0041] When the subject swallows the capsule 1, the capsule 1 moves in the subject's digestive tract by its peristaltic movement. In the meantime, the capsule 1 transmits images taken through the camera 35 to the remote control system at specified time intervals. The remote control system displays each image from the capsule 1 on the monitor of the remote control system. Therefore, the person in charge of medicine (operator) can grasp the current position of the capsule 1. When it is confirmed based on the image displayed on the monitor that the capsule 1 has arrived at the site where the drug is administered, the operator operates the remote control system and includes a medication command (heating command). The wireless signal is transmitted to the capsule 1 from the power of the remote control system.
[0042] カプセル 1にお!/、て、通信回路 32が投薬指令を受信すると、該投薬指令はヒータ 駆動回路 36に与えられる。ヒータ駆動回路 36は、前記スイッチング素子でバッテリ 3 4の DC電圧をスイッチングすることによって、予め決められた電力をコイル状ヒータ 1 6及び 17に供給し、それによりコイル状ヒータ 16及び 17に収納スペース 3を予め決 められた温度に加熱させる。ここで、コイル状ヒータ 16及び 17がオンされる前は、可 溶融壁 7Aおよび栓 7は溶融されな!/、。可溶融壁 7Aおよび栓 7が消化管内の温度よ りも高い融点を持つ材料から作られるからである。他方、可溶融壁 7Aおよび栓 7はコ ィル状ヒータ 16及び 17がオンされるときに溶融されるので、薬剤室 3a_l及び 3a_2内 の薬剤は混合可能となり、第 1スペース 3aが投薬開口 6を介して外部に開放される。 同時に、作動薬室 3b_l及び 3b_2内の作動薬 19a及び 19bが混合される。その結果 、作動薬 19a及び 19bは体積が膨張して、第 2スペース 3b内の圧力が増加されるの で、可動壁 5が投薬開口 6側に移動される。それにより第 1スペース 3a内の薬剤 8a及 び 8bは、混合されながら投薬開口 6を通して外部に放出される。 [0042] When the communication circuit 32 receives the medication command in the capsule 1, the medication command is given to the heater drive circuit 36. The heater drive circuit 36 uses a switching element to switch the DC voltage of the battery 34, thereby supplying a predetermined power to the coiled heater 1 Supply to 6 and 17, thereby causing the coil heaters 16 and 17 to heat the storage space 3 to a predetermined temperature. Here, before the coil heaters 16 and 17 are turned on, the meltable wall 7A and the plug 7 are not melted! /. This is because the meltable wall 7A and the plug 7 are made of a material having a melting point higher than the temperature in the digestive tract. On the other hand, the meltable wall 7A and the stopper 7 are melted when the coil heaters 16 and 17 are turned on, so that the medicines in the medicine chambers 3a_l and 3a_2 can be mixed, and the first space 3a becomes the dosing opening 6 It is opened to the outside through. At the same time, the agonists 19a and 19b in the agonist chambers 3b_l and 3b_2 are mixed. As a result, the volume of the agonists 19a and 19b expands and the pressure in the second space 3b is increased, so that the movable wall 5 is moved toward the dosing opening 6 side. Thereby, the drugs 8a and 8b in the first space 3a are released to the outside through the dosing opening 6 while being mixed.
[0043] 第 2実施形態では、操作者が遠隔操作システムを通じて投薬指令を送信したときに 、カプセル型投薬装置 Bがコイル状ヒータ 16及び 17をオンして可溶融壁 7Aおよび 栓 7を溶融させる結果、薬剤が消化管内に投与される。この場合、栓 7が溶融するタ イミングのばらつきを低減することができるので、投薬のタイミングを厳密に制御して、 薬剤を所望の部位に確実に投与することができる。牛脂から作られる可溶融壁 7Aが 第 2スペース 3bから第 1スペース 3aに延長され、また可溶融壁 7A及び栓 7が単一片 として形成されるので、それらを同時に溶融することができる。その結果、投薬開口 6 を確実に開口させて、薬剤を消化管内にスムーズに投与することができる。加えて、 可溶融壁 7Aが第 1スペース 3aを薬剤室 3a_l及び 3a_2に仕切るので、予め分離す ることが好ましい異なる薬剤をそれぞれ薬剤室 3a_l及び 3a_2に格納することができ 、異なる薬剤を所望の部位に同時に付与することができる。  In the second embodiment, when the operator transmits a medication command through the remote control system, the capsule-type medication device B turns on the coiled heaters 16 and 17 to melt the meltable wall 7A and the plug 7 As a result, the drug is administered into the digestive tract. In this case, since the variation in the timing at which the stopper 7 melts can be reduced, the drug can be reliably administered to a desired site by precisely controlling the timing of dosing. The meltable wall 7A made from beef tallow is extended from the second space 3b to the first space 3a, and the meltable wall 7A and the plug 7 are formed as a single piece, so that they can be melted simultaneously. As a result, the medication opening 6 can be reliably opened and the drug can be smoothly administered into the digestive tract. In addition, since the meltable wall 7A partitions the first space 3a into the drug chambers 3a_l and 3a_2, different drugs that are preferably separated in advance can be stored in the drug chambers 3a_l and 3a_2, respectively. Can be applied simultaneously to the site.
[0044] 一実施形態において、カプセル型投薬装置 Bはコイル状ヒータ 17のみを備える。こ の実施形態は、可溶融壁 7A及び栓 7をコイル状ヒータ 17のみで溶融することができ る場合に有効である。この場合、導電ライン 12及び 14も不要になるので、製造が容 ：¾である。  In one embodiment, the capsule dosing device B includes only the coiled heater 17. This embodiment is effective when the meltable wall 7A and the plug 7 can be melted only by the coil heater 17. In this case, since the conductive lines 12 and 14 are not required, the production is easy.
[0045] 一実施形態において、カプセル型投薬装置 Bは、カメラ 35に代えてタイマ回路（図 示せず)を備える。該タイマ回路は、所望の待機時間待って、投薬指令をヒータ駆動 回路 36に与えるように構成される。この実施形態では、被験者がカプセル型投薬装 置 Bを嚥下した後に該待機時間が経過したときに、ヒータ駆動回路 36がスイッチング 動作を行ってコイル状ヒータ 16及び 17に電力を供給する。投薬タイミングを被験者 に応じて調整することができるので、薬剤を所望の部位に確実に投与することができ [0045] In one embodiment, the capsule dosing device B includes a timer circuit (not shown) instead of the camera 35. The timer circuit is configured to wait for a desired waiting time and give a medication command to the heater drive circuit 36. In this embodiment, the subject has a capsule dosing device. When the waiting time elapses after swallowing the device B, the heater drive circuit 36 performs a switching operation to supply power to the coiled heaters 16 and 17. The medication timing can be adjusted according to the subject, so that the drug can be reliably administered to the desired site.
[0046] 一実施形態において、栓 7は可溶融壁 7Aから分離された個別片として形成される 。この個別片は、例えばコイル状ヒータ 16及び 17の発熱温度よつて変化しない材料 力、ら作ること力 Sできる。この場合、可溶融壁 7Aはコイル状ヒータ 16及び 17の発熱に より溶融されて、作動薬 19a及び 19bは混合されて体積が膨張する。それにより、可 動壁 5が投薬開口 6側に移動され第 1スペース 3a内の圧力が上昇するので、栓 7が 押し出され、続いて薬剤室 3a_l及び 3a_2内の薬剤 8a及び 8bが投薬開口 6を通して 消化管内に放出される。一例において、栓 7 (個別片）は、前記融点で溶融される材 料から作ってもよい。この場合、栓 7の表面がコイル状ヒータ 16の発熱により溶融され て、栓 7と投薬開口 6との間の隙間が大きくなるので、栓 7を外れやすくでき、薬剤を 所望の部位に確実に投与することができる。 [0046] In one embodiment, the plug 7 is formed as a separate piece separated from the meltable wall 7A. This individual piece can be made of a material force that does not change with the heating temperature of the coiled heaters 16 and 17, for example. In this case, the meltable wall 7A is melted by the heat generated by the coil heaters 16 and 17, and the working chemicals 19a and 19b are mixed to expand the volume. As a result, the movable wall 5 is moved to the side of the medication opening 6 and the pressure in the first space 3a is increased, so that the stopper 7 is pushed out, and subsequently the medications 8a and 8b in the medication chambers 3a_l and 3a_2 are dispensed. Through the gastrointestinal tract. In one example, the plug 7 (individual piece) may be made from a material that is melted at the melting point. In this case, the surface of the stopper 7 is melted by the heat generated by the coiled heater 16, and the gap between the stopper 7 and the dosing opening 6 is increased, so that the stopper 7 can be easily removed, and the medicine is reliably delivered to the desired site. Can be administered.
[0047] 本発明を幾つかの好ましい実施形態について記述した力 この発明の本来の精神 および範囲を逸脱することなぐ当業者によって様々な修正および変形が可能である  [0047] Power describing the invention in several preferred embodiments Various modifications and variations can be made by those skilled in the art without departing from the true spirit and scope of the invention.

Claims

請求の範囲 The scope of the claims
[1] 消化管内に投与されるカプセルと、 [1] a capsule administered into the digestive tract;
投薬開口を持ち該カプセルの一端側内に形成される収納スペースと、  A storage space having a medication opening and formed in one end of the capsule;
該収納スペース内に格納される薬剤と、  A medicine stored in the storage space;
該投薬開口を塞ぐ栓と  A stopper plugging the dosing opening;
を備えるカプセル型投薬装置であって、  A capsule-type dosing device comprising:
該装置は、  The device
該収納スペース内に移動自在に置かれて、該収納スペースを、該投薬開口を含み 該薬剤を格納する第 1スペースと第 2スペースとに仕切ることができる可動壁と、 投薬指令に従って、該栓を該投薬開口から外し、また該可動壁を該投薬開口側に 移動させて該薬剤を該消化管内に投与するための駆動システムと  A movable wall that is movably placed in the storage space and that can divide the storage space into a first space and a second space that contain the medication opening and store the medicine; and in accordance with a medication command, the stopper And a drive system for dispensing the medicament into the gastrointestinal tract by moving the movable wall toward the dosing opening.
を更に備えるカプセル型投薬装置。  A capsule-type dosing device.
[2] 該可動壁は永久磁石から構成され、 [2] The movable wall is composed of a permanent magnet,
該駆動システムは、  The drive system is
該収納スペースを囲む壁のうち該可動壁の両面にそれぞれ対向する両壁にそれ ぞれ形成される一対のスパイラル 'コイルと、  A pair of spiral coils formed respectively on both walls of the wall surrounding the storage space facing both sides of the movable wall; and
該投薬指令に従って該可動壁を該投薬開口側に移動させるように該スパイラル 'コ ィルの各々に給電するための励磁回路と  An excitation circuit for supplying power to each of the spiral coils so as to move the movable wall toward the dosing opening according to the dosing instruction;
を備える請求項 1記載のカプセル型投薬装置。  The capsule-type dosing device according to claim 1, further comprising:
[3] 該栓は、遊動嵌合によって該投薬開口を塞ぎ、 [3] The stopper closes the dosing opening by a loose fit,
該駆動システムは、該可動壁を該投薬開口側に移動させながら、該栓を該投薬開 ロカ、ら外して該薬剤を該消化管内に投与する請求項 2記載のカプセル型投薬装置。  3. The capsule-type dosing device according to claim 2, wherein the drive system moves the movable wall toward the dosing opening and removes the stopper from the dosing locker to administer the drug into the digestive tract.
[4] 該栓は、該消化管内の温度よりも高い融点で溶融される材料から作られ、 [4] The plug is made of a material that is melted at a melting point higher than the temperature in the digestive tract,
該駆動システムは、該投薬開口側の該スパイラル 'コイルのジュール熱で該栓を溶 融させることにより該栓を該投薬開口から外し、続いて該薬剤を該消化管内に投与 する請求項 2記載のカプセル型投薬装置。  3. The drive system removes the plug from the dosing opening by melting the plug with Joule heat of the spiral coil on the dosing opening side, and subsequently dispenses the drug into the gastrointestinal tract. Capsule-type dosing device.
[5] 該消化管内の温度よりも高い融点で溶融される可溶融膜から作られ、該第 2スぺー スを複数の作動薬室に仕切る可溶融壁を更に備え、 該駆動システムは、 [5] It further comprises a meltable wall made of a meltable film that is melted at a melting point higher than the temperature in the digestive tract, and partitions the second space into a plurality of working chemical chambers. The drive system is
該作動薬室にそれぞれ格納され、混合されることで体積が膨張する各種作動薬と、 該収納スペースを囲む壁に形成されるヒータと、  Each of the agonists stored in the agonist chamber and expanded in volume when mixed, a heater formed on a wall surrounding the storage space,
該投薬指令に従って該ヒータに給電するヒータ駆動回路と  A heater drive circuit for supplying power to the heater according to the medication instruction;
を備える請求項 1記載のカプセル型投薬装置。  The capsule-type dosing device according to claim 1, further comprising:
[6] 該栓は、遊動嵌合によって該投薬開口を塞ぎ、 [6] The stopper closes the dosing opening by a loose fit,
該駆動システムは、該可動壁を該投薬開口側に移動させながら、該栓を該投薬開 ロカ、ら外して該薬剤を該消化管内に投与する請求項 5記載のカプセル型投薬装置。  6. The capsule-type dosing device according to claim 5, wherein the drive system moves the movable wall toward the dosing opening and removes the stopper from the dosing opening to administer the drug into the digestive tract.
[7] 該栓は、前記融点で溶融される材料から作られる請求項 5記載のカプセル型投薬 装置。 7. The capsule dosing device according to claim 5, wherein the stopper is made of a material melted at the melting point.
[8] 前記薬剤として複数の薬剤を含み、  [8] including a plurality of drugs as the drug,
該可溶融壁は、該第 1スペースをも複数の薬剤室に仕切るように、該可動壁を貫通 して該第 1スペースに延びるように形成され、  The meltable wall is formed to extend through the movable wall to the first space so as to partition the first space into a plurality of drug chambers,
該複数の薬剤は、それぞれ該複数の薬剤室に格納される  The plurality of medicines are respectively stored in the plurality of medicine chambers.
請求項 5記載のカプセル型投薬装置。  The capsule-type dosing device according to claim 5.
[9] 前記薬剤として複数の薬剤を含み、 [9] including a plurality of drugs as the drug,
該可溶融壁は、該第 1スペースをも複数の薬剤室に仕切るように、該可動壁を貫通 して該第 1スペースに延びるように形成され、  The meltable wall is formed to extend through the movable wall to the first space so as to partition the first space into a plurality of drug chambers,
該複数の薬剤は、それぞれ該複数の薬剤室に格納される  The plurality of medicines are respectively stored in the plurality of medicine chambers.
請求項 7記載のカプセル型投薬装置。  The capsule-type dosing device according to claim 7.
[10] 該栓及び該可溶融壁は、牛脂から作られ互いに一体化される請求項 9記載のカブ セル型投薬装置。 10. The capsule-type dosing device according to claim 9, wherein the stopper and the meltable wall are made of beef tallow and integrated with each other.
PCT/JP2007/071513 2006-11-17 2007-11-06 Capsule-type device for dispensing medicament WO2008059728A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006-312030 2006-11-17
JP2006312029A JP2008125641A (en) 2006-11-17 2006-11-17 Drug administration device
JP2006312030A JP2008125642A (en) 2006-11-17 2006-11-17 Drug administration device
JP2006-312029 2006-11-17

Publications (1)

Publication Number Publication Date
WO2008059728A1 true WO2008059728A1 (en) 2008-05-22

Family

ID=39401537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/071513 WO2008059728A1 (en) 2006-11-17 2007-11-06 Capsule-type device for dispensing medicament

Country Status (1)

Country Link
WO (1) WO2008059728A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011018743A1 (en) 2009-08-12 2011-02-17 Koninklijke Philips Electronics N.V. Medicine reservoir for drug delivery device
JP2012522616A (en) * 2009-04-07 2012-09-27 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Modular oral ingestion drug supply capsule
WO2014053352A1 (en) 2012-10-03 2014-04-10 Danmarks Tekniske Universitet Ingestible capsule for remote controlled release of a substance
JP2016531623A (en) * 2013-09-26 2016-10-13 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ Delivery capsule with threshold release

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030114A1 (en) * 2003-09-29 2005-04-07 Olympus Corporation Capsule dosing system, dosing method using capsule dosing system, and control method for capsule dosing system
JP2005143991A (en) * 2003-11-18 2005-06-09 Olympus Corp Capsule type medical system
JP2005185567A (en) * 2003-12-25 2005-07-14 Olympus Corp Medical capsule apparatus
JP2006061399A (en) * 2004-08-26 2006-03-09 Hitachi Ltd Examination capsule and examination system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030114A1 (en) * 2003-09-29 2005-04-07 Olympus Corporation Capsule dosing system, dosing method using capsule dosing system, and control method for capsule dosing system
JP2005143991A (en) * 2003-11-18 2005-06-09 Olympus Corp Capsule type medical system
JP2005185567A (en) * 2003-12-25 2005-07-14 Olympus Corp Medical capsule apparatus
JP2006061399A (en) * 2004-08-26 2006-03-09 Hitachi Ltd Examination capsule and examination system

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522616A (en) * 2009-04-07 2012-09-27 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Modular oral ingestion drug supply capsule
WO2011018743A1 (en) 2009-08-12 2011-02-17 Koninklijke Philips Electronics N.V. Medicine reservoir for drug delivery device
CN102811762A (en) * 2009-08-12 2012-12-05 皇家飞利浦电子股份有限公司 Medicine Reservoir For Drug Delivery Device
JP2013501568A (en) * 2009-08-12 2013-01-17 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Pharmaceutical storage tank for drug delivery device
US8852155B2 (en) 2009-08-12 2014-10-07 Medimetrics Personalized Drug Delivery Medicine reservoir for drug delivery device
WO2014053352A1 (en) 2012-10-03 2014-04-10 Danmarks Tekniske Universitet Ingestible capsule for remote controlled release of a substance
JP2016531623A (en) * 2013-09-26 2016-10-13 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ Delivery capsule with threshold release

Similar Documents

Publication Publication Date Title
WO2008059728A1 (en) Capsule-type device for dispensing medicament
Munoz et al. A review of drug delivery systems for capsule endoscopy
FI82600B (en) AGRICULTURAL AGRICULTURAL AGRICULTURE FOR FOUNDATION.
US6953455B2 (en) Medicine delivery system
EP2544668B1 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
JPH05228128A (en) Capsule for medical treatment
JP2008513077A (en) Substance delivery device
WO2004026281A2 (en) Micro-reservoir osmotic release systems and microtube array device
JP2006150061A (en) Drug delivery system, and medicine capsule and signal transmitter used for the same
JP2014000414A (en) Apparatus and method for deployment of therapeutic device using catheter
US10610282B2 (en) Medical ablation devices and methods
US20160220482A1 (en) Solid drug delivery apparatus and formulations and methods of use
JP5670326B2 (en) Electronic pill with multiple drug reservoirs
WO2011018743A1 (en) Medicine reservoir for drug delivery device
JP2008125642A (en) Drug administration device
WO2004041068A2 (en) Guided capsule for wireless endoscopy, biopsy, and drug delivery
US20040020173A1 (en) Low temperature anodic bonding method using focused energy for assembly of micromachined systems
RU2761368C2 (en) Control device for electrosurgical instrument
JP2008125641A (en) Drug administration device
CN100482294C (en) Remote controlled modicine reliesing electronic capsule capable of partly degradation
US20200281489A1 (en) Agent-Delivering Neural Probe Devices And Related Systems And Methods
Hosseini Micro-electromechanical system based electronic capsules (MEMS) aimed at optimizing drug delivery to the human body
US20190365460A1 (en) Medical ablation devices and methods
JP2023537916A (en) ingestible drug delivery device
WO2004062717A1 (en) Method and mechanism for medicine dispenser

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07831245

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07831245

Country of ref document: EP

Kind code of ref document: A1